GlassScriptPhysician profile
Laura Schoenberg
NPI 1588642243
$69,901.77
in general payments reported to CMS, 2019-2025
68 companies · $7,088 in 2025
The $7,088 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $11K · 2021: $9,857 · 2022: $8,686 · 2023: $10K · 2024: $6,709 · 2025: $7,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,821 · Consulting Fee: $150 · Education: $63.57 · Travel and Lodging: $50.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19,971.10 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,821.37 |
| Consulting Fee | $150.00 |
| Education | $63.57 |
| Travel and Lodging | $50.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $25,645.93 | 2019-2025 | |
| Abbvie INC. | $6,347.15 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Neurelis, INC. | $5,457.41 | 2020-2024 | Valtoco |
| Biogen, INC. | $2,500.63 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Teva Pharmaceuticals USA, INC. | $2,102.98 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Ucb, INC. | $2,055.58 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Genentech USA, INC. | $1,800.70 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Neurocrine Biosciences, INC. | $1,656.67 | 2019-2025 | Ingrezza |
| Sk Life Science, INC. | $1,568.39 | 2020-2025 | Xcopri |
| Alexion Pharmaceuticals, INC. | $1,415.40 | 2019-2025 | Ultomiris |
| Lundbeck LLC | $1,227.51 | 2019-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $1,103.23 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Pfizer INC. | $1,086.43 | 2020-2025 | |
| Tg Therapeutics, INC. | $1,065.34 | 2023-2025 | |
| Amgen INC. | $893.55 | 2019-2025 | Uplizna |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Schoenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.